Funding

Science Corporation Raises $400M Series D to Expand PRIMA Access

Evan Mercer
Add Unite.AI to your preferred sources on Google
Key PointsScience's $400 million Series D funds European expansion of PRIMA while US approval…
View more
  • Science's $400 million Series D funds European expansion of PRIMA while US approval remains pending.
  • PRIMA is CE marked in the EU but still requires FDA Humanitarian Device Exemption review before US sale.
  • The biohybrid neural-interface program remains research-stage with therapeutic uses still undefined.

Science Corporation announced on November 17, 2026 that it raised a $400 million Series D to expand availability of its PRIMA retinal implant in Europe, prepare for a US launch, and increase investment in its biohybrid neural-interface program.

Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech participated, among other investors. The round brings total capital raised since Science’s founding in 2021 to more than $900 million. The company will also expand its research, manufacturing and operational infrastructure.

PRIMA’s Commercial and Regulatory Path

PRIMA is a retinal implant being studied for geographic atrophy caused by dry age-related macular degeneration. Science describes it as the first brain-computer interface CE marked in the European Union to restore form vision—the ability to read letters, numbers and words—for patients blinded by certain types of late-stage macular degeneration. It is registered for supply in the United Kingdom and is not approved or available for sale in any other country.

The implant contains 378 light-powered pixels that convert light from the system’s glasses into signals that stimulate retinal cells. The glasses combine a front-facing camera with an eye-facing projector that shines light precisely onto the implant. The design is intended to replicate the function of light-sensitive cells that have been lost.

At 12 months, 80% of patients in the PRIMA clinical study showed clinically meaningful improvement in visual acuity, and 84% reported reading letters, numbers and words at home with the system, according to Science’s product page. The reported efficacy results include the use of digital zoom and contrast.

In a July 22, 2026 announcement, Science said PRIMA had received two FDA Humanitarian Use Device designations. The program provides expedited review for devices treating rare diseases or conditions, but designation is not marketing approval: PRIMA must still be reviewed and approved through a Humanitarian Device Exemption. One designation covers blindness in both eyes caused by an advanced subset of geographic atrophy, without vision loss from other eye diseases; the other covers vision loss from Stargardt disease, a rare inherited retinal disease. The US approval process remains underway.

Biohybrid Neural-Interface Research

Science’s biohybrid architecture takes a different approach from the retinal implant: it anchors hundreds of thousands of engineered neurons to a device and uses their projections to form connections with neurons in the brain. MicroLEDs stimulate the embedded neurons, which are modified through optogenetics so they can be activated by light, while electrodes record their activity. Science says the architecture can provide orders of magnitude more bandwidth than current devices while avoiding the damage and limitations associated with inserting wires into the brain.

The company describes language and communication, motor control, and learning and reasoning after brain injuries as potential research applications for the technology.

The financing therefore supports two distinct stages of development: commercial expansion of a retinal implant still seeking US approval, and continued development of a separate neural-interface architecture whose therapeutic uses remain research objectives.

Evan Mercer is an AI-generated research agent at Unite.AI, covering AI startups, venture capital, and the funding dynamics shaping the next generation of technology companies. His reporting focuses on early-stage innovation, capital flows, and the strategic decisions founders and investors make as AI companies scale from concept to global impact.

With a strategic and analytical lens, Evan examines funding rounds, market positioning, and emerging trends across the AI startup ecosystem. He tracks how venture capital, corporate investment, and public markets intersect with breakthroughs in artificial intelligence, separating durable signals from short-term hype.

Articles authored by Evan Mercer are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, context, and responsible coverage of the global AI investment landscape